COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
A2Z Smart Technologies Corp. Announces Aggregate US$4.7 Million Registered Direct Offering of Common Shares and Common Warrants, Inclusive of $1.5 Million Raised in December 2023
A2Z Smart Technologies Corp. has announced a definitive securities purchase agreement to issue common shares and warrants in a registered direct offering, expecting to raise aggregate gross proceeds equal to US$3.23 million. The net proceeds will be used for working capital and general corporate purposes. The offering is subject to customary closing conditions and is expected to close on or around Monday, January 8, 2024. -
COMMUNIQUÉ DE PRESSE
Pulsar Announces Investor Awareness Agreements
Pulsar Helium Inc. (TSXV:PLSR) has entered into advertising and investor awareness campaign agreements with Tailfin Capital, Miriad Limited, Martin City Studios, GoldInvest Consulting, and NAI Interactive. These agreements aim to enhance market and brand awareness, investor engagement, and shareholder connections. The agreements include a variety of services such as digital media, marketing, data analytics, investor relations, media, consultancy, audio interviews, investor relation services, and public relations. The company's president and CEO, Thomas Abraham-James, expressed excitement for the comprehensive strategy's implementation in 2024 and emphasized its potential impact during an active time for Pulsar. -
COMMUNIQUÉ DE PRESSE
Eagle Plains Announces Management Transition
Eagle Plains Resources Ltd. (TSXV:EPL) has announced a planned senior management transition to lead the company into the coming years. The transition includes the resignation of Tim J. Termuende as President and CEO, the appointment of Charles C. (Chuck) Downie as President and CEO, the addition of Jesse T. Campbell to the Board of Directors, and changes in roles for other key personnel. The company remains financially healthy with significant cash in treasury, investments, and real estate assets, and continues to pursue mineral exploration projects with a focus on critical metals in western Canada. For further information, please visit their website. -
COMMUNIQUÉ DE PRESSE
Shareholder Update: Review of 2023 and Outlook for 2024
Aztec Minerals Corp. (TSXV:AZT)(OTCQB:AZZTF) provides a review of 2023 and its outlook for 2024, highlighting advancements in its projects and corporate side, including the Tombstone Project's drilling program and the Cervantes Project's exploration program. The company appointed a new CFO, raised $2.6 million in equity financings, and is well positioned to create substantial shareholder value in 2024. The press release also provides details on the 2023 highlights and the 2024 outlook for Aztec Minerals Corp. -
COMMUNIQUÉ DE PRESSE
Zomedica Announces Publication of Research Validating Better Patient Acceptance of PulseVet(R) Electro-hydraulic Shock Wave Therapy without Sedation Utilizing Novel “X-Trode” Handpiece
Zomedica Corp. announced the publication of an article validating the ability to better utilize PulseVet electro-hydraulic shock wave therapy in awake canine patients without sedation. The article describes the use of a novel shockwave trode, reinforcing current clinical evidence on the effectiveness of electro-hydraulic shock wave therapy for various indications. The article was written by Dr. Gina L. Joseph and team at Colorado State University and is available on Frontiers in Veterinary Science. In addition, CSU is evaluating PulseVet therapy for slowing the progression of canine osteoarthritis, with expected results later in 2024. The ability to treat patients without sedation using X-Trode is seen as a major advancement. Zomedica's Vice President of Clinical and Veterinary Affairs, Adrian Lock, expressed excitement for the upcoming study to further validate the therapy's efficacy. The company's CEO, Larry Heaton, believes the publication will accelerate the acceptance of shock wave therapy for small animal patients. PulseVet's shock wave therapy harnesses high-energy sound waves to stimulate cells, promoting healing growth factors. Zomedica's commitment to advancing veterinary care is evident through ongoing clinical studies and product innovations. The company's mission to address the unmet needs of clinical veterinarians underscores its dedication to animal welfare and better veterinary practice. For more information, readers can visit Zomedica's website. -
COMMUNIQUÉ DE PRESSE
NanoViricides to Present at the Biotech Showcase in San Fransisco
NanoViricides, Inc., a leader in antiviral therapies based on nanomedicines technology, is set to present at the Biotech Showcase™ 2024 in San Francisco. The presentation will include an update on the successful Phase 1 clinical trials of NV-CoV-2 Oral Syrup and Oral Gummies, which contain the novel antiviral nanomachine NV-387. The company's President will discuss how NV-387 addresses the unmet need for a broad-spectrum antiviral drug as well as its potential across multiple virus families. With its wide spectrum of antiviral activity, NV-387 has the potential to revolutionize antiviral treatment, much like antibiotics did for bacterial infections. -
COMMUNIQUÉ DE PRESSE
Tryp Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial for the Treatment of Fibromyalgia at The University of Michigan
Tryp Therapeutics Inc. is pleased to announce the dosing of the first patient in a Phase 2a clinical trial for fibromyalgia using their proprietary IV-infused psilocin, TRP-8802. With positive results, the company aims to further develop TRP-8803 to provide relief to millions of patients suffering from chronic pain. Learn more about Tryp's innovative therapies at www.tryptherapeutics.com. -
COMMUNIQUÉ RÉGLEMENTÉ
Edenred - Disclosure of Share Capital and Voting Rights as of December 31, 2023
This press release discloses the share capital and voting rights of Edenred as of December 31, 2023, in accordance with the French Commercial Code and the General Regulations of the Autorité des marchés financiers. The total shares outstanding, potential voting rights, and exercisable voting rights are provided, excluding rights attached to shares held in treasury. More information can be found on edenred.com, Investors/Shareholders section then Regulated Information. -
COMMUNIQUÉ RÉGLEMENTÉ
Edenred - Déclaration du nombre d'actions et de droits de vote au 31 décembre 2023
Edenred déclare le nombre d'actions et de droits de vote conformément à la réglementation en vigueur. Toute l’information est disponible sur le site web edenred.com, rubrique Investisseurs / Actionnaires
